Aileron Therapeutics, Inc.: Clinical stage oncology company conducting 3 clinical trials for its lead candidate, ALRN-6924, a first-in-class/best-in-class drug that targets the p53 pathway. ALRN-6924 is from the Stapled peptide platform and is the only clinical drug candidate that binds equipotently to both of the p53 suppressor proteins, MDMX and MDM2. This company has now initiated of a Phase 1 / 1b in Acute Myeloid Leukemia (AML) and a Phase 2a in Peripheral T-Cell Lymphoma.
Based in...
US - New England
Clinical Stage
Phase l or ll
Disease Space
Public, USA
Market Cap
Therapeutic Modalities
Platform Technology
490 Arsenal Way
Suite 210
Cambridge, MA 02472
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Top 10 Holders of Aileron Therapeutics, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Armistice Capital LLC 5.47 1,460,620 1.61 Stakes 2019-12-31
Renaissance Technologies LLC 1.79 477,181 0.52 13F 2020-03-31
Banco Bilbao Vizcaya Argentaria SA 1.70 454,250 0.50 13F 2020-03-31
BBVA Asset Management SA SGIIC 1.68 449,475 0.49 Funds 2020-03-31
William Blair & Co. LLC 1.14 303,944 0.33 13F 2020-03-31
The Vanguard Group, Inc. 0.84 224,318 0.25 Funds 2020-05-31
Vanguard Group, Inc. (Subfiler) 0.84 224,318 0.25 13F 2020-03-31
Geode Capital Management LLC 0.41 110,674 0.12 13F 2020-03-31
Game Plan Financial Advisors LLC 0.23 61,900 0.07 13F 2020-03-31
BlackRock Fund Advisors 0.16 42,588 0.05 13F 2020-03-31
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.